Rein Therapeutics downgraded to Hold from Buy at Brookline

Brookline analyst Kemp Dolliver downgraded Rein Therapeutics (RNTX) to Hold from Buy without a price target The company’s Q2 update was “disappointing” as it is is still waiting for a meeting with the FDA regarding the clinical hold of the Phase 2 RENEW trial, the analyst tells investors in a research note. The firm cites funding concerns and Rein ‘s lack of progress on the clinical hold for the downgrade.